Research programme: respiratory tract disorders therapeutics - Allinaire Therapeutics

Drug Profile

Research programme: respiratory tract disorders therapeutics - Allinaire Therapeutics

Alternative Names: Antibody therapeutics - Allinaire Therapeutics; Pulmonary diseases therapeutics - Allinaire Therapeutics

Latest Information Update: 14 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indiana University School of Medicine
  • Class Antibodies
  • Mechanism of Action Immunomodulators; Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Chronic obstructive pulmonary disease; Respiratory tract disorders

Most Recent Events

  • 12 Feb 2018 Allinaire Therapeutics receives SBTTR phase I grant from National Heart, Lung, and Blood Institute (NHLBI) for development of Respiratory tract disorders therapeutics
  • 19 Sep 2017 Allinaire Therapeutics receives SBIR phase II grant from National Institutes of Health for the development of Respiratory tract disorders therapeutics
  • 06 Mar 2017 Research programme: respiratory tract disorders therapeutics - Allinaire Therapeutics is available for licensing as of 06 Mar 2017. http://www.allinaire.com/partners/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top